News

Stay up to date on the latest company news and scientific headlines.

PerioPredict® Genetic Risk Test Incorporated Into Freedom Dental Plan

Delivers additional access to fully covered preventative care for patients at increased risk for periodontal disease identified through PerioPredict

WALTHAM, MA – April 21, 2016Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin’s PerioPredict® Genetic Risk Test as part of CBA’s Freedom Dental Plan.

PerioPredict identifies individuals at increased risk for severe periodontitis due to a genetic tendency to over-produce chronic inflammation, an underlying root cause of many chronic diseases. The test […]

Interleukin Genetics Announces Clarification of Commercial Test Compliance

Interleukin and the U.S. Food and Drug Administration have reached alignment on compliance status of Interleukin’s genetic tests

WALTHAM, MA – April 5, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions with the U.S. Food and Drug Administration (FDA) in response to an Untitled Letter issued by the FDA on November 4, 2015 and a meeting on February 3, 2016 with personnel within FDA’s Office of In Vitro Diagnostics and Radiological Health (OIR) to discuss Interleukin’s written response to OIR with respect to the Untitled Letter.  Interleukin believes it has maintained a constructive relationship with the […]

Interleukin Genetics Announces Clinical Study to Evaluate Impact of PerioPredict® Genetic Risk Testing on Dental Patient Engagement and Preventative Care

Study aims to broaden evidence in support of medical and economic value of PerioPredict® genetic testing platform

WALTHAM, MA – March 29, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced Institutional Review Board (IRB) approval for a clinical study to assess the impact of the Company’s PerioPredict Genetic Risk Test on dental patient engagement for more preventive dental care. The study will build on Interleukin Genetics’ evidence base in support of the medical and economic value of the PerioPredict genetic testing platform.

PerioPredict identifies individuals at increased risk for severe periodontitis because they have a genetic tendency to over-produce chronic inflammation, […]

Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results

Progress in Executing Commercial Plan Underscored by Recent Agreement with Metagenics, Inc.

Conference Call and Webcast Today at 8:30 a.m. EDT

WALTHAM, MA – March 17, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2015.
“2015 was an important year for Interleukin Genetics, as we focused on developing and executing a significantly updated strategic and operational plan centered on the medical value of our genetic test, PerioPredict®,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics. “We position PerioPredict as the cornerstone of enhanced benefits designs and employer-sponsored wellness initiatives to identify high-risk individuals for proactive outreach and personalized care. We believe these programs […]

Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare Through Targeted Management of Systemic Inflammation

World-renowned team to advise on building practical population health initiatives

 

WALTHAM, MA – March 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.

“We are extremely pleased to bring together a ‘dream team’ of international experts at the intersection of systemic and […]

Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results

WALTHAM, MA – March 15, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s fourth quarter and year-end 2015 financial results.

Thursday March 17th, 8:30 a.m. (ET)

Dial in (domestic):                  877-324-1976

Dial in (international):            631-291-4550

Conference ID:                        62665317

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com. 

 

About Interleukin Genetics.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions.  The products empower individuals and their healthcare providers to manage […]

Interleukin Genetics and Metagenics Enter into Agreement to Incorporate PerioPredict® into Metagenics’ Employee Benefit Plan

WALTHAM, MA – February 18, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, and Metagenics, Inc., a global pioneer in science-based nutrition and wellness, today announced the signing of an agreement to provide Interleukin’s PerioPredict test to Metagenics’ employees as part of an enhanced employee benefits program.  PerioPredict will be used to identify individuals who may benefit from reduction of their systemic inflammatory burden as an approach to enhance prevention and management of chronic diseases.

Under the terms of the agreement, Interleukin will provide genetic testing and patient education to Metagenics employees, as well as dental professional support to their dental providers.

“We are […]

Interleukin Genetics Reports Third Quarter 2015 Financial Results

WALTHAM, Mass. – November 12, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.

“Since joining Interleukin Genetics in April, I have been focused on developing a strategic and operational plan that will lay the groundwork for driving market adoption of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to over-produce inflammation.  Elevated inflammation is implicated in numerous chronic diseases.” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.

“We are encouraged by the reception of our enhanced positioning that outlines medical value for managing inflammation through practical dental interventions”, Mr. Carbeau continued.  “Medical studies now document the role of systemic inflammation in […]

Interleukin Genetics Reports Second Quarter 2015 Financial Results

Company to Host Conference Call Today at 8:30 a.m. ET

WALTHAM, Mass. – August 14, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.

“Interleukin Genetics is advancing on its mission to prevent and more cost-effectively manage chronic diseases,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “We have enhanced the positioning of PerioPredict®, our genetic test that identifies individuals with a life-long predisposition to produce inflammation, to target patients with chronic conditions such as diabetes and cardiovascular disease who will benefit from increased dental care. Engaging these high-risk Individuals provides significant leverage to improve wellness and lower costs, builds on the strong foundation […]

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results

WALTHAM, Mass. – August 7, 2015 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company’s second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company’s website at 52.2.148.42.  The webcast will be archived following the call at 52.2.148.42.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and […]